Holen Sie sich die Stockscreener-App
0.3861
4.22%
-0.017
Schlusskurs vom Vortag:
$0.4031
Offen:
$0.401
24-Stunden-Volumen:
845.15K
Relative Volume:
0.15
Marktkapitalisierung:
$17.67M
Einnahmen:
$16.77M
Nettoeinkommen (Verlust:
$-11.87M
KGV:
-0.8142
EPS:
-0.4742
Netto-Cashflow:
$-5.90M
1W Leistung:
-8.46%
1M Leistung:
-21.68%
6M Leistung:
-56.61%
1J Leistung:
-77.55%
1-Tages-Spanne:
$0.3725
$0.419
1-Wochen-Bereich:
$0.3725
$0.449
52-Wochen-Spanne:
$0.3248
$2.4299
Immunoprecise Antibodies Ltd Stock (IPA) Company Profile
Firmenname
Immunoprecise Antibodies Ltd
Sektor
Branche
Telefon
-
Adresse
-
Vergleichen Sie IPA mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
IPA
Immunoprecise Antibodies Ltd
|
0.3861 | 17.67M | 16.77M | -11.87M | -5.90M | -0.4742 |
|
VRTX
Vertex Pharmaceuticals Inc
|
484.24 | 124.35B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
700.33 | 76.56B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
644.48 | 39.16B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
250.59 | 32.44B | 2.25B | -278.16M | -42.59M | -2.17 |
|
BNTX
Biontech Se Adr
|
120.01 | 28.77B | 3.30B | -501.07M | 1.03B | -2.1146 |
Immunoprecise Antibodies Ltd Stock (IPA) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2022-12-02 | Eingeleitet | H.C. Wainwright | Buy |
| 2021-10-25 | Eingeleitet | The Benchmark Company | Buy |
Immunoprecise Antibodies Ltd Aktie (IPA) Neueste Nachrichten
ImmunoPrecise Antibodies Transfers to Nasdaq Capital Market, Gains Extension - TipRanks
Immunoprecise Antibodies Announces Transfer To Nasdaq Capital Market And Extension Of Bid Price Compliance Period - Marketscreener.com
Can ImmunoPrecise's New Nasdaq Strategy Save Its Market Position? - StockTitan
ImmunoPrecise Antibodies Ltd (IPA) Shares Up Despite Recent Market Volatility - The News Heater
Check Out ImmunoPrecise Antibodies Ltd (IPA)’s Trade Data Rather Than the Analysts’ Views - SETE News
ImmunoPrecise Antibodies Ltd (IPA) presents a great opportunity, but the stock is slightly overvalued - US Post News
ImmunoPrecise Antibodies Boosts Financial Position Through Successful Capital Initiatives - TipRanks
ImmunoPrecise Antibodies (OTCMKTS:IPATF) Shares Down 3.9% – Here’s Why - Defense World
ImmunoPrecise Antibodies Ltd. (IPA) Unveils AI-Developed GLP-1 Therapies for Type 2 Diabetes and Obesity, Pioneering New Frontiers in Biotech Innovation - Insider Monkey
ImmunoPrecise Antibodies (IPA) Announces Completion of At-the-Market Equity Offering and Full Conversion of Yorkville Debenture - The Globe and Mail
ImmunoPrecise Antibodies Strengthens Financial Position with Strategic Capital Initiatives - TipRanks
ImmunoPrecise Antibodies (NASDAQ:IPA) Subsidiary BioStrand Introduces Breakthrough AI Model In Life Sciences, Harnessing LLM Stacking And HYFT Technology - ACCESS Newswire
Benchmark maintains Buy on Immunoprecise stock, target at $3.00 - MSN
Benchmark maintains Buy on Immunoprecise stock, target at $3.00 By Investing.com - Investing.com Canada
Immunoprecise uses AI to develop new class of GLP-1 therapies - BioWorld Online
ImmunoPrecise Antibodies develops new class of GLP-1 therapies through AI - Yahoo Finance
Stock Traders Buy High Volume of ImmunoPrecise Antibodies Call Options (NASDAQ:IPA) - Defense World
What's Going On With ImmunoPrecise Antibodies Stock Wednesday? - Benzinga
S&P 500 Growth (IGX) QuotePress Release - The Globe and Mail
TSX Renewable and Clean Tech Index (TXCT) QuotePress Release - The Globe and Mail
TSX 60 Index (TXSX) QuotePress Release - The Globe and Mail
TSX Venture Composite Index (JX) QuotePress Release - The Globe and Mail
TSX Global Mining Index (TXGM) QuotePress Release - The Globe and Mail
IPA (ImmunoPrecise Antibodies) Pioneers AI-Designed GLP-1 Therap - GuruFocus.com
ImmunoPrecise Antibodies Leverages AI for Next-Gen Diabetes Treatment - TipRanks
IPA (ImmunoPrecise Antibodies) Pioneers AI-Designed GLP-1 Therapies: A Potential New Chapter in Diabetes Treatment - Business Wire
ImmunoPrecise Antibodies Ltd. (IPA) Launches AI-Powered Drug Discovery Pipeline, Revolutionizing Therapeutic Development with LENSai™ Platform - Insider Monkey
10 Trending AI Stocks on Latest News and Ratings - Insider Monkey
ImmunoPrecise launches AI-driven drug discovery pipeline - Investing.com India
ImmunoPrecise launches AI-driven drug discovery pipeline By Investing.com - Investing.com Canada
ImmunoPrecise Antibodies Launches AI-Powered Drug Discovery Platform - TipRanks
ImmunoPrecise Antibodies Realigns Pipeline Strategy, Empowering Drug Discovery with AI and First-Principles Innovation - Business Wire
Even With A 30% Surge, Cautious Investors Are Not Rewarding ImmunoPrecise Antibodies Ltd.'s (NASDAQ:IPA) Performance Completely - Simply Wall St
ImmunoPrecise Launches Groundbreaking AI Platform LENSai for Revolutionary Drug Discovery - StockTitan
ImmunoPrecise Antibodies (NASDAQ:IPA) Stock Price Up 15.5% – What’s Next? - Defense World
ImmunoPrecise Antibodies Announces CFO Resignation - TipRanks
ImmunoPrecise Antibodies finance chief to step down - MSN
ImmunoPrecise Antibodies announces resignation of CFO - Yahoo Finance
ImmunoPrecise Antibodies Ltd. Announces the Resignation of Kristin Taylor as Chief Financial Officer, Effective January 16, 2025 - Marketscreener.com
ImmunoPrecise Antibodies CFO Resignation and Succession - TipRanks
ImmunoPrecise Antibodies CFO Kristin Taylor Announces Resignation, Will Transition Through January 2025 - StockTitan
IPA Announces Resignation of Chief Financial Officer - Business Wire
ImmunoPrecise Antibodies (IPA) Demonstrates Strong Market Confidence with Insider Share Purchases - The Globe and Mail
ImmunoPrecise CEO Leads Major $306K Insider Stock Purchase, Signals Confidence in AI-Driven Strategy - StockTitan
ImmunoPrecise Antibodies to Present at Microcap Conference 2025: AI-Driven Biotech Showcase - StockTitan
Finanzdaten der Immunoprecise Antibodies Ltd-Aktie (IPA)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.27%
3.05%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):